Fuchikami et al.
|
2011
|
Promoter I Promoter IV
|
chr11:27743473–27744564
chr11:27722840–27723980
|
Major depression (MDD)
|
Peripheral blood
|
20 MDD, 18 CT
|
EpiTYPER
|
CpG8,9—75.7 %
CpG76—54.3 %
CpG80,81—79.1 %
For rest CpGs—>80 %
|
D’Addario et al.
|
2012
|
Promoter I
|
chr11:27744031–27744193
|
Bipolar disorder I, II (BDI, BDII)
|
Peripheral blood
|
49 BD I, 45 BD II, 52 CT
|
Methylation-specific real-time PCR
|
BDII vs CT—62.5 %
Antidep. vs antidep-free—93 %
|
D’Addario et al.
|
2013
|
Promoter I
|
chr11:27744031–27744193
|
Major depression
|
Peripheral blood
|
41 MDD, 44 CT
|
Methylation-specific real-time PCR
|
Methylation level —83.1 %
Expression level—65.9 %
|
Ikegame et al.
|
2013
|
Promoter I Promoter IV
|
chr11:27743390–27743763
chr11:27722994–27723372
|
Schizophrenia (SCZ)
|
Peripheral blood
|
100 SCZ, 100 CT
|
Bisulfite pyrosequencing
|
CpG72—52.4 %
|
Perroud et al.
|
2013
|
Promoter I Promoter IV
|
chr11:27743862–27744057
chr11:27723057–27723293
|
Borderline personality disorder (BPD)
|
Peripheral blood
|
115 BPD, 52 CT
|
High resolution melt analysis
|
BPD vs CT—100 %
|
Dell’Osso et al.
|
2014
|
Promoter I
|
chr11:27744031–27744194
|
Bipolar disorder I, II, major depression
|
Peripheral blood
|
43MDD, 61 BD I, 50 BD II, 44 CT
|
Methylation-specific real-time PCR
|
MDD, BDII vs BDI and CT—100 %
|
Kleimann et al.
|
2015
|
Promoter I Promoter IV Promoter VI
|
chr11:27743416–27744782 (3 regions) chr11:27723103–27723511
chr11:27722216–27722863 (2 regions)
|
Treatment-resistant major depression (electroconvulsive therapy)
|
Peripheral blood
|
11MDD
|
Direct bisulfite sequencing
|
Remit. vs non-remit. 4 treatment sessions: 91–100 %
|
Chagnon et al.
|
2015
|
Promoter I Exon III Promoter VI/Exon VI
|
NS
|
Anxiety/major depression
|
Saliva
|
19 MDD, 24 CT
|
Bisulfite pyrosequencing
|
MDD vs CT—86.3 %
CT gen. MDD vs CT gen. CT—88.3 %
|
Keller et al.
|
2010
|
Promoter IV
|
chr11:27723126–27723144 (4 CpG sites)
|
Major depression, suicide
|
Brain (Wernicke area)
|
44 SU, 33 CT
|
Bisulfite pyrosequencing, direct bisulfite sequencing, EpiTYPER
|
CpG1—98.1 %
CpG3—96.3 %
Average level—98.3 %
|
Kordi-Tamandani et al.
|
2012
|
Promoter IV
|
NS
|
Schizophrenia
|
Peripheral blood
|
80 SCZ, 71 CT
|
Methylation-specific PCR
|
Methylation level—99 %
Expression level—94 %
|
Tadic et al.
|
2014
|
Promoter IV
|
chr11:27723103–27723380
|
Major depression (antidepressant treatment)
|
Peripheral blood
|
39 MDD
|
Direct bisulfite sequencing
|
NA
|
Thaler et al.
|
2014
|
Promoter IV
|
chr11:27722840–27723980
|
Bulimic nervosa (BN),
Borderline personality disorder
|
Peripheral blood
|
64 BN(F), 32 CT
|
EpiTYPER
|
BN vs CT—in average for all CpG sites—99.8 %
|
Kang et al.
|
2013
|
Promoter VI
|
chr11:27721688–27721823
|
Major depressive, suicidal behavior (antidepressant treatment)
|
Peripheral blood
|
108 MDD
|
Bisulfite pyrosequencing
|
Previous suicidal attempt—76.7 %
Suicidal ideation during treatment—83.6 and 96.6 %
|
Kang et al.
|
2015a
|
Promoter VI
|
chr11:27721688–27721823
|
Depression related to breast cancer
|
Peripheral blood
|
74 D, 235 CT
|
Bisulfite pyrosequencing
|
D vs CT within 1 week and 1 year in average—81.2 %
|
Kang et al.
|
2015b
|
Promoter VI
|
chr11:27721688–27721823
|
Late-life depression
|
Peripheral blood
|
101 D, 631 CT
|
Bisulfite pyrosequencing
|
D vs CT at baseline and after 2 years in average—97.7 %
|
Unternaehrer et al.
|
2015
|
Exon VI
|
chr11:27721543– 277221857
|
Low maternal care (LC) vs. high maternal care (HC)
|
Peripheral blood
|
45 LC, 40 HC
|
EpiTYPER
|
NA
|
Mill et al.
|
2008
|
Promoter IX
|
chr11:27679911–27680006
|
Schizophrenia, bipolar disorder
|
Brain (frontal cortex)
|
35 SZ, 35 BD, 35 CT
|
Enriched unmethylated DNA microarray, bisulfite pyrosequencing
|
Val homozygotes (78) vs Met carries (27)—100 %
|